• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines

1-(2-Tetrahydrofuroyl)piperazine Hydrobromide: A Comprehensive Overview

1-(2-Tetrahydrofuroyl)piperazine Hydrobromide (CAS No. 63590-62-5) is a compound of significant interest in the fields of organic chemistry and pharmacology. This compound is characterized by its unique structure, which combines a piperazine ring with a tetrahydrofuran moiety, making it a valuable molecule for both academic research and potential therapeutic applications. The CAS number serves as a standardized identifier, ensuring consistency in scientific communication and regulatory compliance.

The synthesis of 1-(2-Tetrahydrofuroyl)piperazine Hydrobromide involves a series of well-defined chemical reactions, including nucleophilic substitution and acid-base neutralization. Recent advancements in synthetic methodologies have enabled the efficient production of this compound with high purity, which is essential for its use in preclinical studies. The piperazine ring is a key structural element, contributing to the molecule's flexibility and ability to form hydrogen bonds, which are critical for its pharmacological activity.

From a pharmacological perspective, 1-(2-Tetrahydrofuroyl)piperazine Hydrobromide has shown promising results in various assays. Studies conducted in vitro have demonstrated its ability to modulate ion channels, particularly those involved in neuronal signaling. This suggests potential applications in the treatment of neurological disorders such as epilepsy and chronic pain. Recent research has also highlighted its selectivity for certain receptor subtypes, which could be exploited to develop targeted therapies with reduced off-target effects.

The tetrahydrofuran moiety plays a crucial role in the compound's pharmacokinetic profile. It enhances solubility and bioavailability, making it more amenable for systemic administration. Advanced computational modeling techniques have been employed to predict the molecule's behavior in biological systems, providing insights into its absorption, distribution, metabolism, and excretion (ADME) properties. These studies are pivotal for optimizing drug delivery systems and improving therapeutic outcomes.

In terms of applications, 1-(2-Tetrahydrofuroyl)piperazine Hydrobromide has been extensively studied as a lead compound for drug discovery programs. Its structural versatility allows for further modifications to enhance potency and selectivity. Collaborative efforts between academic institutions and pharmaceutical companies have led to the identification of analogs with improved pharmacodynamic properties. These advancements underscore the importance of interdisciplinary research in advancing medicinal chemistry.

Looking ahead, the development of 1-(2-Tetrahydrofuroyl)piperazine Hydrobromide into clinical trials will depend on rigorous safety assessments and efficacy studies. Regulatory agencies require comprehensive data on toxicity profiles and pharmacokinetics before granting approval for human testing. Encouragingly, preliminary results from animal studies indicate that the compound exhibits acceptable safety margins, paving the way for further investigation.

In conclusion, 1-(2-Tetrahydrofuroyl)piperazine Hydrobromide (CAS No. 63590-62-5) represents a compelling candidate for drug development due to its unique chemical structure and promising pharmacological properties. Continued research efforts will undoubtedly shed light on its full potential as a therapeutic agent across diverse disease states.

• 547730-06-3(1,4-Bis(tetrahydro-2-furanyl)carbonyl-piperazine)
• 412334-56-6(1-Piperazinyl(2R)-tetrahydro-2-furanylmethanone)
• 452351-77-8(1-[(tetrahydro-2-furyl)carbonyl]piperidine)
• 63035-27-8(1-(oxolane-2-carbonyl)-1,4-diazepane)
• 83867-86-1(N,N-diethyltetrahydrofuran-2-carboxamide)
• 63074-07-7(1-(oxolane-2-carbonyl)piperazine)
• 83608-91-7(8-Oxa-3-azabicyclo[3.2.1]octan-2-one,3-acetyl-)
• 1226871-68-6((3-methyl-1-piperazinyl)(tetrahydro-2-furanyl)-Methanone)
• 600159-66-8(N,N-dimethyltetrahydrofuran-2-carboxamide)
• 545373-12-4((4-ethyl-1-piperazinyl)(tetrahydro-2-furanyl)methanone)